# Kazia Therapeutics Limited (KZIA)

Source: https://www.quantisnow.com/company/KZIA
Generated: 2026-11-15T18:10:57.136Z

- Ticker: KZIA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001075880
- Website: kaziatherapeutics.com

## About

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

## Latest KZIA news and filings

- 2026-11-12 12:00 UTC [Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader](https://www.quantisnow.com/insight/kazia-therapeutics-to-host-virtual-event-on-december-2-2026-6786023)
- 2026-11-02 21:01 UTC [SEC Form NT 20-F filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-nt-20-f-filed-by-kazia-therapeutics-limited-6766936)
- 2026-11-02 12:00 UTC [Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium](https://www.quantisnow.com/insight/kazia-therapeutics-announces-two-abstracts-on-paxalisib-tumor-and-immune-6766026)
- 2026-10-30 11:20 UTC [Analyst Coverage Initiated] [Needham initiated coverage on Kazia Therapeutics with a new price target](https://www.quantisnow.com/insight/needham-initiated-coverage-on-kazia-therapeutics-with-a-new-price-6764503)
- 2026-10-29 11:00 UTC [Conference Announcement] [Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference](https://www.quantisnow.com/insight/kazia-therapeutics-to-participate-in-fireside-chat-at-guggenheim-3rd-6762364)
- 2026-10-21 10:55 UTC [Analyst Coverage Initiated] [Guggenheim initiated coverage on Kazia Therapeutics with a new price target](https://www.quantisnow.com/insight/guggenheim-initiated-coverage-on-kazia-therapeutics-with-a-new-price-6752788)
- 2026-10-20 11:39 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on Kazia Therapeutics with a new price target](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-kazia-therapeutics-with-a-new-6751433)
- 2026-09-22 12:04 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6722459)
- 2026-09-22 12:03 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6722453)
- 2026-09-22 12:02 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6722452)
- 2026-09-22 12:01 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6722450)
- 2026-09-22 12:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kazia-therapeutics-limited-6722436)
- 2026-09-22 11:30 UTC [Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders](https://www.quantisnow.com/insight/kazia-therapeutics-announces-sovargen-co-doses-first-patient-in-phase-6722350)
- 2026-09-18 20:03 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6720440)
- 2026-09-18 20:03 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6720439)
- 2026-09-18 20:03 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6720433)
- 2026-09-18 20:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kazia-therapeutics-limited-6720413)
- 2026-09-18 20:02 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6720407)
- 2026-09-09 11:30 UTC [Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer](https://www.quantisnow.com/insight/kazia-therapeutics-announces-first-patient-dosed-in-pnoc035-clinical-study-6709234)
- 2026-09-01 20:55 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kazia-therapeutics-limited-6701704)
- 2026-09-01 20:55 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6701701)
- 2026-09-01 20:55 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6701700)
- 2026-09-01 20:56 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6701699)
- 2026-09-01 20:56 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6701698)
- 2026-09-01 11:30 UTC [Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy](https://www.quantisnow.com/insight/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-6700526)
- 2026-09-01 11:15 UTC [Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer](https://www.quantisnow.com/insight/kazia-therapeutics-expands-paxalisib-clinical-trial-into-hrher2--breast-cancer-6700490)
- 2026-08-31 21:58 UTC [Public Offering] [Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering](https://www.quantisnow.com/insight/kazia-therapeutics-limited-announces-oversubscribed-closing-of-up-to-120-6700165)
- 2026-08-31 11:34 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6699098)
- 2026-08-31 11:33 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6699095)
- 2026-08-31 11:32 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6699093)
- 2026-08-31 11:31 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6699092)
- 2026-08-31 11:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kazia-therapeutics-limited-6699090)
- 2026-08-31 10:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kazia-therapeutics-limited-6698970)
- 2026-08-31 10:09 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-kazia-therapeutics-limited-6698958)
- 2026-08-28 11:30 UTC [Public Offering] [Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering](https://www.quantisnow.com/insight/kazia-therapeutics-limited-announces-pricing-of-up-to-120-million-6697906)
- 2026-08-28 10:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-kazia-therapeutics-limited-6697855)
- 2026-08-28 10:08 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-kazia-therapeutics-limited-6697854)
- 2026-08-27 20:47 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-kazia-therapeutics-limited-6697391)
- 2026-08-27 20:44 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6697384)
- 2026-08-27 20:43 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Kazia Therapeutics Limited](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-kazia-therapeutics-limited-6697375)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/KZIA
- Earnings history: https://www.quantisnow.com/earnings/KZIA
- Dividend history: https://www.quantisnow.com/dividends/KZIA
- Insider transactions: https://www.quantisnow.com/insiders/KZIA
- Options chain: https://www.quantisnow.com/options/KZIA
- SEC 8-K filings only: https://www.quantisnow.com/company/KZIA/8-k
- RSS and alerts for KZIA: https://www.quantisnow.com/docs/rss-feeds.md